NCT03311945View on ClinicalTrials.gov

Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM

PHASE3CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 2, 2018

Primary Completion Date

March 30, 2021

Study Completion Date

November 30, 2022

Conditions
HIV InfectionsHIV-1-infectionHIV Seropositivity
Interventions
DRUG

Raltegravir

Raltegravir (1200 mg QD)

DRUG

Lamivudine

Lamivudine (300 mg QD)

Trial Locations (1)

08036

Hospital Clínic i Provincial de Barcelona, Barcelona

All Listed Sponsors
collaborator

Fundacion Clinic per a la Recerca Biomédica

OTHER

lead

Judit Pich

OTHER

NCT03311945 - Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM | Biotech Hunter | Biotech Hunter